Latest from University of Cincinnati Cancer Institute

John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.
Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).
Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.
Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.
Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.
The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.
Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy
Publication Bottom Border
Border Publication